<code id='3F57FFE06F'></code><style id='3F57FFE06F'></style>
    • <acronym id='3F57FFE06F'></acronym>
      <center id='3F57FFE06F'><center id='3F57FFE06F'><tfoot id='3F57FFE06F'></tfoot></center><abbr id='3F57FFE06F'><dir id='3F57FFE06F'><tfoot id='3F57FFE06F'></tfoot><noframes id='3F57FFE06F'>

    • <optgroup id='3F57FFE06F'><strike id='3F57FFE06F'><sup id='3F57FFE06F'></sup></strike><code id='3F57FFE06F'></code></optgroup>
        1. <b id='3F57FFE06F'><label id='3F57FFE06F'><select id='3F57FFE06F'><dt id='3F57FFE06F'><span id='3F57FFE06F'></span></dt></select></label></b><u id='3F57FFE06F'></u>
          <i id='3F57FFE06F'><strike id='3F57FFE06F'><tt id='3F57FFE06F'><pre id='3F57FFE06F'></pre></tt></strike></i>

          leisure time

          leisure time

          author:hotspot    Page View:6379
          Chemotherapy infusion
          The White House outlined its efforts to end shortages of three key generic chemotherapies. But experts want more more details. Gerry Broome/AP

          WASHINGTON — The White House says it’s working to end shortages of three key generic chemotherapies. But experts said the administration would have to provide more details to fully mitigate the health care system’s concerns.

          Carboplatin, cisplatin, and methotrexate are three of 15 cancer drugs in shortage in the United States. They have been staples of cancer treatment for decades, according to a White House blog post, but their supply in the United States has been nearly halved in the past year. The shortages have forced doctors to ration the drugs and alter treatment plans, leaving cancer patients to wonder whether their survival odds are hurt.

          advertisement

          In its blog post, the White House noted that it’s now allowing Chinese imports of cisplatin. The Food and Drug Administration is also working with generic drug companies to boost production of all three drugs, but it didn’t say which companies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more
          JPM 2024: Verve Therapeutics looks to mainstream genome editing
          JPM 2024: Verve Therapeutics looks to mainstream genome editing

          VerveTherapeuticsCEOSekarKathiresanVerveSANFRANCISCO—Thepromiseofgenomeeditinghasgivenrisetopotentia

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          JPM 2024: Verve Therapeutics looks to mainstream genome editing

          VerveTherapeuticsCEOSekarKathiresanVerveSANFRANCISCO—Thepromiseofgenomeeditinghasgivenrisetopotentia